Loading
A phase 1/2 trial of Aldesleukin, Avelumab, Nivolumab in metastatic cancer and melanoma, run by Aulos Bioscience, Inc., now recruiting.
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer is a phase 1/2 interventional study registered as NCT05267626 by Aulos Bioscience, Inc., with 159 participants planned, started 2022-04-04 and due to reach its primary completion in 2027-02-28. Interventions recorded: AU-007, Aldesleukin, Avelumab, Nivolumab. Conditions listed: Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Avelumab, Nivolumab, Small-cell lung cancer, Melanoma.
Shares TIL therapy, Cytokines & engineered cytokines, Melanoma.
Shares Aldesleukin (high-dose IL-2), Cytokines & engineered cytokines.
Shares Avelumab, Metastatic cancer (cancer that has spread).
Shares TIL therapy, Melanoma.
Shares Aldesleukin (high-dose IL-2), Cytokines & engineered cytokines.
Shares TIL therapy, Melanoma.
Shares Cytokines & engineered cytokines, Melanoma.